Quanterix Corporation

Ladies and gentlemen, thank you for standing by, and welcome to the Quinterix Corporation Q4 2021 Earnings Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask your question during the session, you will need to press star 1 on your telephone. If you require any further assistance, please press star 0. I would now like to hand the conference over to your speaker for today, Mike Doyle. Please go ahead.

Thanks very much. Good morning, everyone, and thanks for joining us today. With me on today's call is Kevin Rosovsky, our chairman and CEO, and Massoud Touloui, our president. Before we begin, I'd like to remind you about a few things. The call will be recorded and will be available on the investor resources section of our website. Today's call will contain forward-looking statements that are based on management's beliefs and assumptions and on information available as of the date of this call. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, assumptions, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. The risks and uncertainties that we face are described in our most recent filings with the Securities and Exchange Commission. During today's conference call, we will discuss some financial measures that are not presented in accordance with U.S. generally accepted accounting principles or non-GAAP financial measures. In the Q4 earnings release and in the appendix of our presentation, which are available on our website, you will find additional disclosures regarding these non-GAAP measures, including reconciliations of these measures to comparative GAAP measures. We believe that these non-GAAP financial measures provide investors with relevant period-to-period comparison of our operations. These financial measures are not recognized under GAAP and should not be considered in isolation or as a substitute for a measure of financial performance prepared in accordance with GAAP. With that, I will turn the call over to Kevin.

Thank you very much, Mike. Looking forward to today's call. We have a very full agenda. We're going to start by describing a really exciting opportunity where we're going to be further expanding our leadership with Massoud going to be taking the CEO role for me starting on April 25th. So this is just an announcement to let you know that this is a very orderly plan that we're going to be rolling out over the next month and a half. But with that, um, after we talk through the transition, I'd like to go through our very, um, significantly positive full year results and Q4 results for 2021. Um, The major announcement this morning on our collaboration with Eli Lilly, which I think is a seminal announcement that has been a major focus for our company for the last several years. Also like to describe the neurodiagnostic therapy of evolution. It's a concept that we laid out and rolled out about a year ago, and it's moving very productively along. And close off with just the precision health proteomics, the role that we're playing in and the world that we think we're going to be able to play over the next several years. And then Mike, I was going to ask you to do financial results and then I'll close with just finalizing some of the compelling dimensions of our current equity. So Massoud, you know, really excited to have you evolve. You and I met each other a couple of years ago, and I just really believe that you have all the capability and we, you and I've been together kind of nonstop for the last year. So really excited for you to evolve into the CEO role and give me a chance to continue evolving strategically at a pretty important moment for our company as the executive chairman of the board and focusing and obviously advising and working closely with you, Masoud, but also working on some of the more important strategic initiatives that we see coming over the next year or so. Now with that, Masoud, would you like to make some comments?